Tesamorelin

Origin and Approval

Tesamorelin is a synthetic analogue of human growth hormone releasing hormone (GHRH) developed by the Montreal-based biotech Theratechnologies. Structurally, it is the full 44-residue human GHRH sequence with a trans-3-hexenoic acid group attached to the N-terminal tyrosine — a modification that protects the peptide against dipeptidyl peptidase-4 (DPP-4) cleavage and extends its biological half-life enough to support once-daily subcutaneous dosing. Tesamorelin is marketed as Egrifta (and more recently the room-temperature-stable reformulation Egrifta SV) and remains one of the very few GHRH analogues with a current FDA approval.

The FDA first approved tesamorelin in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That remains its only FDA-approved indication. Egrifta SV, a more stable formulation with reduced cold-chain requirements, was approved in 2019.

Why Tesamorelin Reduces Visceral Fat Specifically

HIV-associated lipodystrophy is a syndrome of abnormal fat redistribution — accumulation of visceral (intra-abdominal) adipose tissue and loss of subcutaneous fat — historically associated with long-term antiretroviral therapy. Unlike cosmetic abdominal fat, visceral fat is metabolically active, strongly associated with insulin resistance, dyslipidemia, and cardiovascular risk, and is resistant to lifestyle-based fat-loss strategies.

Tesamorelin stimulates physiologic, pulsatile GH release through the same GHRH receptor engaged by Modified GRF 1-29 and sermorelin. Elevated GH and downstream IGF-1 exert a preferential lipolytic effect on visceral adipose tissue, which expresses higher GH-receptor densities than subcutaneous depots. The clinical consequence is a reduction in visceral fat with minimal effect on subcutaneous fat — the specific outcome that defines the lipodystrophy indication.

Clinical Evidence

The registrational program comprised two pivotal Phase 3 trials published in the New England Journal of Medicine in 2007 and subsequent follow-on studies. In the pooled 26-week data, tesamorelin 2 mg subcutaneously daily produced approximately 15–18% reductions in visceral adipose tissue on CT imaging versus placebo, alongside modest improvements in triglycerides and the cholesterol ratio. Benefits were maintained over 52 weeks of continued treatment in extension studies and reversed on discontinuation — tesamorelin is a chronic-use therapy, not a one-and-done intervention.

Beyond the approved indication, tesamorelin has been investigated for non-alcoholic fatty liver disease (NAFLD) in HIV-positive populations and for cognitive and body-composition effects in older adults. None of these secondary applications have yielded an FDA approval.

Practical Considerations

The labeled dose is 2 mg subcutaneously once daily, typically injected into the abdomen at bedtime on an empty stomach to align with the natural nocturnal GH pulse and to avoid blunting by postprandial insulin and amino-acid elevations. Full visceral-fat response develops over roughly 6 months, and continued dosing is required to maintain the effect. Egrifta SV has simplified storage — the original Egrifta required refrigeration and complex reconstitution that was a known barrier to adherence.

Unlike exogenous growth hormone, tesamorelin preserves somatotropic-axis feedback — IGF-1 elevation eventually dampens further GH release — so overshoot into acromegalic IGF-1 ranges is uncommon at labeled doses. This is the pharmacologic argument for GHRH analogues over direct GH administration in metabolically sensitive populations.

Safety Profile

The most clinically meaningful safety consideration is glucose metabolism. GH elevation is counter-regulatory to insulin, and tesamorelin has been associated with dose-dependent increases in fasting glucose and HbA1c, and with new-onset or worsened diabetes in a minority of patients. Baseline glycemic assessment and periodic monitoring are part of standard clinical use. Injection-site reactions, arthralgia, peripheral edema, and myalgia are common; tesamorelin carries contraindications for active malignancy and pregnancy, and for disrupted hypothalamic-pituitary axis function (including pituitary tumor, surgery, or radiation).

Regulatory and Anti-Doping Status

Tesamorelin is Schedule-unrestricted but prescription-only in the US, held an orphan-drug designation for HIV lipodystrophy, and is listed on the World Anti-Doping Agency prohibited list at all times under class S2 (peptide hormones). It is one of only a handful of peptides on this library with both a current FDA approval and a well-characterized Phase 3 evidence base — a combination that is genuinely rare in the GH-axis space and that distinguishes tesamorelin from research-chemical GHRH analogues like CJC-1295 DAC.

Bottom Line

Tesamorelin is the best-validated GHRH analogue in clinical use. Its approved indication is narrow, and its side-effect profile — particularly around glucose — is meaningful enough to warrant proper prescribing rather than self-directed use.